Results 81 to 90 of about 16,068 (199)

KALSIFILAKSIS PADA SEORANG PENDERITA DENGAN CHRONIC KIDNEY DISEASE – MINERAL BONE DISORDER YANG MENJALANI HEMODIALISIS REGULER

open access: yes, 2023
 Abstrak: Kalsifilaksis pada Seorang Penderita dengan Chronic Kidney Disease – Mineral Bone Disorder yang Menjalani Hemodialisis Reguler. Kalsifilaksis merupakan komplikasi dari Chronic Kidney Disease – Mineral Bone Disorder (CKD-MBD). Kondisi ini jarang
Parmelia, Manik, Sutarka, I Nyoman
core   +1 more source

Uremic lion face syndrome

open access: yesBrazilian Journal of Nephrology, 2019
Mineral bone disorder is a common feature of chronic kidney disease. Lion face syndrome is rare complication of severe hyperparathyroidism in end-stage renal disease patients, which has been less commonly reported due to dialysis and medical treatment ...
Joana Gameiro   +3 more
doaj   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner   +10 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

open access: yesObesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu   +5 more
wiley   +1 more source

Chronic Kidney Disease with Mineral Bone Disorder and Vascular Calcification: An Overview

open access: yesLife
Chronic kidney disease (CKD) is a global health issue with a rising prevalence, affecting 697.5 million people worldwide. It imposes a substantial burden, contributing to 35.8 million disability-adjusted life years (DALYs) and 1.2 million deaths in 2017.
Carmine Izzo   +11 more
doaj   +1 more source

Vascular Calcification and Renal Bone Disorders

open access: yesThe Scientific World Journal, 2014
At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and bone composition start to change. This alteration is known as chronic kidney disease-mineral bone disorder (CKD-MBD). It is well known that the bone turnover disorder
Kuo-Cheng Lu   +3 more
doaj   +1 more source

Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India

open access: yesIndian Journal of Endocrinology and Metabolism, 2016
Background: Disordered mineral metabolism is common complications of chronic kidney disease (CKD). However, there are limited data on the pattern of these disturbances in Indian CKD population.
Sanjay Vikrant, Anupam Parashar
doaj   +1 more source

Iron Physiology and Its Impact on Atopic Diseases: An EAACI Taskforce Report

open access: yesAllergy, EarlyView.
ABSTRACT Iron is essential for oxygen transport, energy metabolism, and immune regulation. Yet iron deficiency is the most common micronutrient disorder across all age groups, affecting nearly one quarter of the global population. Iron deficiency triggers nutritional immunity, a host defense mechanism that withholds and redistributes iron, contributing
Franziska Roth‐Walter   +19 more
wiley   +1 more source

Bone Mineral Disease After Kidney Transplantation

open access: yes, 2021
Chronic kidney disease-mineral bone disorder (CKD-MBD) after kidney transplantation is a mix of pre-existing disorders and new alterations. The final consequences are reflected fundamentally as abnormal mineral metabolism (hypercalcemia, hypophosphatemia)
Torregrosa, JV   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy